Abstract: Certain benzylphosphonic acid compounds, and their pharmaceutically-acceptable salts, are inhibitors of tyrosine kinase enzymes, and so are useful for the control of tyrosine kinase dependent diseases (e.g., cancer, atherosclerosis).

Abstract: A solid, non-hygroscopic salt of the Formula (I) ##STR1## wherein R.sup.1 is hydroxy or alkyl;A is C.sub.1 to C.sub.

Abstract: New derivatives of cyclohexane in substantially pure form suitable as pharmaceutical, foodstuff or as a stabilizer.

Abstract: New derivatives of cyclohexane in substantially pure form suitable as a pharmaceutical, foodstuff or as a stabilizer.

Abstract: The use of a compound of the formula I ##STR1## in which V is an alkyl group, fluorine, chlorine, bromine, or iodine, n is an integer from 1 to 5, W is an alkyl, alkenyl, alkynyl or alkoxy group, cyanide, nitro, carboxyl, hydrogen or a cycloalkyl, aryl, aralkyl or carboalkoxy group, R.sup.1 and R.sup.2 are an alkyl, alkenyl, alkynyl, cycloalkyl or halogenoalkyl group, sodium, potassium, calcium, magnesium, aluminum, lithium, ammonium, triethylammonium or hydrogen, R.sup.1 and R.sup.2 together form a cyclic diester, R.sup.3 and R.sup.4 are an alkyl, alkenyl, alkynyl, carboalkoxy, cycloalkyl or alkoxy group, hydrogen, fluorine, chlorine, bromine or iodine and X, Y and Z are oxygen or sulfur, for the treatment of diseases caused by DNA viruses or RNA viruses is described.

Abstract: An alkenoic acid derivative of the formula ##STR1## in which X and Y are identical or different and represent sulfur, sulfoxide, sulfone, an alkylene chain, --SCH.sub.2 --, or oxygen or a direct bond,W represents --CH.dbd.CH--or --CH.sub.2 --CH.sub.2 --,o represents a number 1 to 5,A and B are identical or different and represent carboxyl, carboxymethylene, tetrazolyl or tetrazolylmethylene, or --CO.sub.2 R.sup.9 or --CH.sub.2 CO.sub.2 R.sup.9 or --CONR.sup.10 R.sup.11 or nitrilen represents a number 1 to 10,m represents a number 0 to 7,T and Z are identical or different and represent oxygen or a direct bond andR.sup.2, R.sup.3, R.sup.8 are identical or different and represent hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano or nitro andR.sup.9 is lower alkyl and R.sup.10 and R.sup.11 are hydrogen, lower alkyl, alkylsulfonyl or arylsulfonyl or together are an alkylene chain to form a ringand pharmaceutically acceptable salts thereof.

Abstract: P,P-dihydrocarbylphosphinoacetic acids are prepared by reacting an alkyl ethynyl ether (preferably ethyl ethynyl ether) and/or a haloacetaldehyde acetal (preferably bromoacetaldehyde diethyl acetal) with a basic alkali metal compound (preferably lithium diisopropylamide), followed by coupling with a least one halodihydrocarbylphosphine (preferably chlorodiphenylphosphine or chlorodiethylphosphine or chlorodi(t-butyl)phosphine or chlorodicyclohexylphosphine) and subsequent hydrolysis.

Abstract: A process for the preparation of vinyl phosphonic derivatives of the general formula I ##STR1## in which R.sup.1 and R.sup.2 are the same or different and may stand for hydrogen or a C.sub.1 -C.sub.8 -alkyl, a C.sub.6 -C.sub.10 -aryl, or a C.sub.8 -C.sub.10 -aralkyl radical optionally substituted by Cl or Br, and in which R.sup.1 and R.sup.2 may alternatively be joined together to form an alicyclic ring having from 3 to 12 carbon atoms in the ring, wherein an ethane phosphonic ester of the general formula II ##STR2## in which R.sup.3 and R.sup.4 have the meanings stated above for R.sup.1 and R.sup.2 except for hydrogen and X denotes a hydroxy group, a halogen atom, or a radical of the formula--OR.sup.5,in which R.sup.5 is a hydrogen atom or a radical of the formula ##STR3## in which R.sup.6 is a C.sub.1 -C.sub.6 -alkyl radical or an alicyclic ring, is converted in the gas phase in the presence of a solid catalyst.

Abstract: Compounds which are inhibitors of cholesterol biosynthesis (by inhibiting de novo squalene biosynthesis), and thus are useful as hypocholesterolemic agents and antiatherosclerotic agents, are provided which have the structure ##STR1## wherein R.sup.2 is a metal ion, lower alkyl or H; R.sup.3 is a metal ion or lower alkyl;R is R.sup.1 --(CH.sub.2).sub.n --, R.sup.1 --(CH.sub.2).sub.m --O-- or R.sup.1 --(CH.sub.2).sub.m --OCH.sub.2 --, wherein n is 1 to 4 and m is 0 to 3, andR.sup.1 is R.sup.5 --Q.sup.1 --Q.sup.2 --Q.sup.3 -- wherein R.sup.5, Q.sup.1, Q.sup.2 and Q.sup.3 are as defined herein.New intermediates, new methods of preparation and a method for using such compounds to inhibit cholesterol biosynthesis are also provided.

Abstract: Layered divalent metal pentavalent metallate, M(HAO.sub.4).sub.x (RAO.sub.3).sub.y (Z).sub.z wherein M is divalent metal, A is a pentavalent metal, e.g. phosphorus, R is a substituent group other than H or OH, e.g., phenyl, covalently bonded to A, x+y=1, y is greater than 0, z ranges from 0 to 2, inclusive, and Z is an intercalated moiety is prepared by contacting a source of divalent metal with a substituted phosphonic acid-type compound under hydrothermal conditions.

Abstract: Novel phosphonic acid-containing compounds such as (2-(4-ethenylphenyl)ethenyl)-phosphonic acid and esters thereof are disclosed. A method of preparation of the phosphonic acids comprising contacting a diethylenically unsaturated aromatic compound and phosphorus pentachloride in the presence of sulfur dioxide is also disclosed.The compounds of this invention are useful as monomers for the preparation of polymers having enhanced anti-corrosive properties.

Abstract: Novel salts of methylphosphonic acid with primary amines are described. These compounds are preferably used as extreme pressure additives in lubricant compositions.

Abstract: Layered divalent metal pentavalent metallate, M(HAO.sub.4).sub.x (RAO.sub.3).sub.y (Z).sub.z wherein M is divalent metal, A is a pentavalent metal, e.g. phosphorus, R is a substituent group other than H or OH, e.g., phenyl, covalently bonded to A, x+y=1, y is greater than O, z ranges from 0 to 2, inclusive, and Z is an intercalated moiety is prepared by contacting a source of divalent metal with a substituted phosphonic acid-type compound under hydrothermal conditions.

Abstract: Phosphonic acid, phosphinic acid and phosphine oxide derivatives of the general formula ##STR1## where A, B and R.sup.1 to R.sup.5 have the meanings stated in the description, processes for their preparation, pharmaceutical agents containing them, and their use for the treatment of acne and psoriasis are described .

Abstract: Novel salts of methylphosphonic acid with primary amines are described. These compounds are preferably used as extreme pressure additives in lubricant compositions.